NeuBase Therapeutics (NBSE) PT Lowered to $15 at Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Hartaj Singh lowered the price target on NeuBase Therapeutics (NASDAQ: NBSE) to $15.00 (from $17.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
